DOI: 10.1001/jamanetworkopen.2026.36432 ISSN: 2574-3805

Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma

Garth W. Strohbehn, Josiah D. Nieto, Daniel A. Goldstein, Alex K. Bryant

This comparative effectiveness research study examines outcomes associated with pembrolizumab and nivolumab among US veterans with advanced, unresectable, or metastatic melanoma.